AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37479515 — intervention group
Group type: EXPERIMENTAL
Intervention: MCED blood test (intervention arm)
Number of subjects: 700
Study 37479519 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy of 5 days
Number of subjects: 564
Study 37479519 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy of at least 7 days
Number of subjects: 564
Study 37479520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest daily
Number of subjects: 0
Study 37479520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37479520 — intervention group
Group type: COMPARATOR
Intervention: Overall in-study group
Number of subjects: 0
Study 37479524 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation (PBM) with a placebo cosmetic
Number of subjects: 54
Study 37479524 — intervention group
Group type: COMPARATOR
Intervention: Placebo cosmetic
Number of subjects: 54
Study 37479526 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests
Number of subjects: 855
Study 37479526 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 855
Study 37479547 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d)
Number of subjects: 46
Study 37479547 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib (K) + Dexamethasone (d)
Number of subjects: 46
Study 37479616 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 262
Study 37479616 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 262
Study 37479616 — intervention group
Group type: COMPARATOR
Intervention: PPV
Number of subjects: 262
Study 37479616 — intervention group
Group type: COMPARATOR
Intervention: No PPV
Number of subjects: 262
Study 37479616 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pneumococcal carriage
Number of subjects: 262
Study 37479627 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient comfort management solutions identified through qualitative interviews
Number of subjects: 25
Study 37479627 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic radiographers' comfort management solutions identified through qualitative interviews
Number of subjects: 25
Study 37479795 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese cohort
Number of subjects: 69
Study 37479795 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese cohort with stable-increased body weight
Number of subjects: 69
Study 37479795 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese cohort who had not lost weight
Number of subjects: 69
Study 37479795 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-1 levels
Number of subjects: 69
Study 37479795 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning cortisol levels
Number of subjects: 69
Study 37479795 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted pituitary intensity
Number of subjects: 69
Study 37479812 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring (RPM) for hypertension
Number of subjects: 288
Study 37479812 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 288
Study 37479853 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood serotonin levels
Number of subjects: 105
Study 37479853 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood TPH1 levels
Number of subjects: 105
Study 37480004 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical CoQ10 (40% CoQ10) mucoadhesive tablets, 3 times daily for one month
Number of subjects: 34
Study 37480004 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid (triamcinolone acetonide 0.1% 5-g adhesive paste), 4 times daily for one month
Number of subjects: 34
Study 37480005 — intervention group
Group type: EXPERIMENTAL
Intervention: TB/HIV group
Number of subjects: 0
Study 37480005 — intervention group
Group type: EXPERIMENTAL
Intervention: TB group
Number of subjects: 0
Study 37480005 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV group
Number of subjects: 0
Study 37480005 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-classical monocytes
Number of subjects: 0
Study 37480005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate monocytes
Number of subjects: 0
Study 37480005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional monocytes
Number of subjects: 0
Study 37480087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weaning of opioids (morphine or methadone)
Number of subjects: 0
Study 37480087 — intervention group
Group type: COMPARATOR
Intervention: Slow weaning of opioids (morphine or methadone)
Number of subjects: 0
Study 37480132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided vascular access (USG)
Number of subjects: 200
Study 37480132 — intervention group
Group type: COMPARATOR
Intervention: Palpation insertion (C)
Number of subjects: 200
Study 37480164 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (anti-CD33 antibody-drug conjugate)
Number of subjects: 0
Study 37480164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 37480164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplant (HSCT) in first remission
Number of subjects: 0
Study 37480164 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care measures
Number of subjects: 0
Study 37480362 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 6-month (PP6M)
Number of subjects: 178
Study 37480391 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise cTnI
Number of subjects: 19
Study 37480391 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 relaxation times
Number of subjects: 19
Study 37480391 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) dysfunction
Number of subjects: 19
Study 37480391 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular global longitudinal strain
Number of subjects: 19
Study 37480410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-positive patients
Number of subjects: 382
Study 37480410 — intervention group
Group type: COMPARATOR
Intervention: Aspergillus-negative patients
Number of subjects: 382
Study 37480410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus presence
Number of subjects: 382
Study 37480432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant low-potency topical corticosteroids (TCS) every 4 weeks for 16 weeks
Number of subjects: 162
Study 37480432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant low-potency topical corticosteroids (TCS)
Number of subjects: 162
Study 37480432 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concomitant low-potency topical corticosteroids (TCS)
Number of subjects: 162
Study 37480520 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 cream applied twice a week for 4 weeks
Number of subjects: 0
Study 37480520 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice a week for 4 weeks
Number of subjects: 0
Study 37480520 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 cream
Number of subjects: 0
Study 37480520 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 37480797 — intervention group
Group type: EXPERIMENTAL
Intervention: smART+ -guided nutrition
Number of subjects: 98
Study 37480797 — intervention group
Group type: COMPARATOR
Intervention: ESPEN-guideline-based nutrition (Control)
Number of subjects: 98
Study 37480800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cardioversion mean AFR of patients relapsed to AF (332 ± 64 fpm)
Number of subjects: 32
Study 37480800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cardioversion mean AFR of patients maintaining sinus rhythm (378 ± 59 fpm)
Number of subjects: 32
Study 37480840 — intervention group
Group type: EXPERIMENTAL
Intervention: Online sleep diary system (SHUTi intervention)
Number of subjects: 45598
Study 37480908 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal CAD
Number of subjects: 117
Study 37480908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse CAD
Number of subjects: 117
Study 37480994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy plus chemotherapy (HFRT), 60 Gy over 25 fractions, administered five times each week.
Number of subjects: 28
Study 37480994 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy plus chemotherapy (CFRT), 69.96 Gy over 33 fractions, administered five times each week.
Number of subjects: 28
Study 37480994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups experienced acute grade 1 or 2 toxicities including skin toxicity, oral mucositis, difficulty swallowing, xerostomia; no acute grade 3 or 4 toxicities reported.
Number of subjects: 28
Study 37480994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy plus chemotherapy (HFRT).
Number of subjects: 28
Study 37480994 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy plus chemotherapy (CFRT).
Number of subjects: 28
Study 37481003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-action tissue (DAT) clip
Number of subjects: 107
Study 37481065 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-Guided Transrectal Prostate Laser Ablation
Number of subjects: 0
Study 37481150 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (AA)
Number of subjects: 22
Study 37481477 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline whole genome sequencing (WGS)
Number of subjects: 9
Study 37481477 — intervention group
Group type: COMPARATOR
Intervention: Multigene panel testing
Number of subjects: 9
Study 37481493 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation-assisted surgery
Number of subjects: 17
Study 37481515 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI oxaliplatin in combination with modified systemic FOLFIRI plus targeted therapy
Number of subjects: 0
Study 37481515 — intervention group
Group type: COMPARATOR
Intervention: Systemic FOLFIRI plus targeted therapy
Number of subjects: 0
Study 37481608 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation CD19-directed CAR T cells (CARTs)
Number of subjects: 13
Study 37481707 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable flow CPAP device
Number of subjects: 138
Study 37481707 — intervention group
Group type: COMPARATOR
Intervention: Ventilator CPAP
Number of subjects: 138
Study 37481707 — intervention group
Group type: COMPARATOR
Intervention: Bubble CPAP
Number of subjects: 138
Study 37481707 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (general)
Number of subjects: 138
Study 37481756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration group (n=12)
Number of subjects: 24
Study 37481756 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 24
Study 37481816 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) - defined as a combination of a minimum of 3 medications in 4 drug classes (antiplatelet drugs, statins, β blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers).
Number of subjects: 8311
Study 37481816 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 8311
Study 37481816 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) in PCI group
Number of subjects: 8311
Study 37481816 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) in CABG group
Number of subjects: 8311
Study 37482128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair samples from premature neonates
Number of subjects: 45
Study 37482128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged NICU exposure to non-invasive respiratory support devices and gastric tubes
Number of subjects: 45
Study 37482128 — intervention group
Group type: COMPARATOR
Intervention: Healthy control neonates
Number of subjects: 45
Study 37482172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 20 mg/kg/d, twice daily for 4 weeks
Number of subjects: 44
Study 37482172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 37482217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet similar to the DASH diet (25% total fat: 6% SFA)
Number of subjects: 166
Study 37482217 — intervention group
Group type: COMPARATOR
Intervention: Average American diet (AAD) (37% total fat: 16% SFA)
Number of subjects: 166
Study 37482499 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive 8-week weight loss program including evidence-based lifestyle recommendations for diet, physical activity, and self-weighing; support through text messages, emails, and video-based problem-solving sessions.
Number of subjects: 28
Study 37482499 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive 8-week weight loss program
Number of subjects: 28
Study 37482512 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical PSMA-PET
Number of subjects: 277
Study 37482512 — intervention group
Group type: COMPARATOR
Intervention: Presurgical CAPRA score alone
Number of subjects: 277
Study 37482564 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 0
Study 37482646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal microbiota of ALS patients
Number of subjects: 66
Study 37482821 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration in addition to diet instructions, pelvic floor exercises, and static abdominal exercises for six weeks
Number of subjects: 40
Study 37482821 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises, static abdominal exercises, and diet instructions
Number of subjects: 40
Study 37482878 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous dentin nanoparticles
Number of subjects: 20
Study 37482878 — intervention group
Group type: COMPARATOR
Intervention: Allograft bone grafts
Number of subjects: 20
Study 37482926 — intervention group
Group type: EXPERIMENTAL
Intervention: Single FMT treatment
Number of subjects: 183
Study 37482926 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated FMT treatments
Number of subjects: 183
Study 37482940 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 396
Study 37482940 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 396
Study 37482992 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga (KY) training
Number of subjects: 22
Study 37482992 — intervention group
Group type: COMPARATOR
Intervention: Memory enhancement training (MET)
Number of subjects: 22
Study 37483071 — intervention group
Group type: EXPERIMENTAL
Intervention: BFI-751
Number of subjects: 0
Study 37483071 — intervention group
Group type: COMPARATOR
Intervention: EU ustekinumab
Number of subjects: 0
Study 37483071 — intervention group
Group type: COMPARATOR
Intervention: US ustekinumab
Number of subjects: 0
Study 37483161 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activation within the first weeks after allo-HSCT
Number of subjects: 85
Study 37483161 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activation
Number of subjects: 85
Study 37483544 — intervention group
Group type: EXPERIMENTAL
Intervention: CM310 (300 mg) every 2 weeks
Number of subjects: 56
Study 37483544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 37483552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 37483552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37483617 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-alpha-trypsin inhibitor heavy chain 4
Number of subjects: 0
Study 37483623 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified immune cell (MIC) infusions
Number of subjects: 25
Study 37483623 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (control)
Number of subjects: 25
Study 37484009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil palm phenolic supplementation
Number of subjects: 0
Study 37484009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37484196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 64
Study 37484196 — intervention group
Group type: COMPARATOR
Intervention: Water cues
Number of subjects: 64
Study 37484196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Taste Test (ATT)
Number of subjects: 64
Study 37484196 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α release in the alcohol cue condition
Number of subjects: 64
Study 37484210 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cortisol (t-Cort) levels in stable outpatients with ACLD
Number of subjects: 137
Study 37484210 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stages of ACLD (S0 to S5)
Number of subjects: 137
Study 37484210 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cortisol (t-Cort) levels
Number of subjects: 137
Study 37484210 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of bile acids and systemic inflammation (interleukin-6 levels)
Number of subjects: 137
Study 37484496 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg SIM0417 plus 100 mg ritonavir
Number of subjects: 32
Study 37484496 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg SIM0417 plus 100 mg ritonavir
Number of subjects: 32
Study 37484496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 37484539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score V.2.0 (graphically modified version with a black 'ultraprocessed' banner)
Number of subjects: 21159
Study 37484539 — intervention group
Group type: COMPARATOR
Intervention: No front-of-pack label (control)
Number of subjects: 21159
Study 37484855 — intervention group
Group type: EXPERIMENTAL
Intervention: Productive art-based activities (2 hours per week for 12 weeks)
Number of subjects: 73
Study 37484855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no productive art-based activity)
Number of subjects: 73
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP integrated into maternal and child health (MCH) clinics
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP training
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory and visual privacy in PrEP and HIV testing service delivery spaces
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision visits
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of PrEP in MCH
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment screening tool (RAST) availability
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP cards availability
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of service and commodity gaps per facility
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Most frequent gaps
Number of subjects: 55
Study 37484872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of gaps by facility level
Number of subjects: 55
Study 37484961 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard program (3 sessions/week for 12 weeks)
Number of subjects: 185
Study 37484961 — intervention group
Group type: COMPARATOR
Intervention: Alternative program (1 session/week for the first four weeks, then 2 sessions/week for the next 16 weeks)
Number of subjects: 185
Study 37485329 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized digital therapeutic group
Number of subjects: 324
Study 37485329 — intervention group
Group type: COMPARATOR
Intervention: Conventional education-based rehabilitation group
Number of subjects: 324
Study 37485383 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (16g)
Number of subjects: 12
Study 37485383 — intervention group
Group type: COMPARATOR
Intervention: Pea sprouts (placebo)
Number of subjects: 12
Study 37485388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 supplementation
Number of subjects: 0
Study 37485388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37485397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple drugs given per routine care
Number of subjects: 0
Study 37485436 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum web- and phone-based lifestyle program
Number of subjects: 44
Study 37485436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored lifestyle counseling by a registered dietitian
Number of subjects: 44
Study 37485564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day on days 1-14 of every 21-day cycle in combination with R-ESHAP at standard doses
Number of subjects: 46
Study 37485589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled oxytocin 240 IU (400 μg) IH
Number of subjects: 31
Study 37485589 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU (17 μg) IM
Number of subjects: 31
Study 37485589 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin 5 IU (8.5 μg) IV
Number of subjects: 31
Study 37485589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled oxytocin (Group 1)
Number of subjects: 31
Study 37485589 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin (Group 1)
Number of subjects: 31
Study 37485589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled oxytocin (Group 2)
Number of subjects: 31
Study 37485887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.8 ± 0.1 mmoL/L [49.9 ± 2.3 mg/dL])
Number of subjects: 63
Study 37485887 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched)
Number of subjects: 63
Study 37486024 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 20
Study 37486082 — intervention group
Group type: EXPERIMENTAL
Intervention: V122I carriers with ATTR-CM
Number of subjects: 278